Preclinical mouse studies in HHD2 transgenic mice

Data has been generated in HHD2 transgenic mice on dendritic cell derived-exosomes (DEX), nanomeric vesicles harboring MHC/peptide complexes capable of promoting primary T cell responses and tumor rejection in the presence of adjuvants. We showed that, in the absence of adjuvants, DEX mediate potent antigen dependent-antitumor effects against preestablished tumors in mice pretreated with immunopotentiating dosing of cyclophosphamide (CTX).

CTX could
i) abolish the suppressive function of CD4+CD25+Foxp3+ regulatory T cells (Treg),
ii) markedly enhance the magnitude of secondary but not primary CTL responsesinduced by DEX vaccines,
iii) synergize with DEX in therapy but not prophylaxis tumor models.

Therefore, therapeutic vaccines such as DEX aimed at boosting tumor-primed effector T cells could benefit procedures that minimize the effects of Treg.

• organism type
• Mus musculus

• cell type
• dendritic cell,
• cytotoxic T lymphocyte,
• regulatory t cell

• cell component type
• extracellular vesicular exosome

• molecule type
• cyclophosphamide,
• FOXP3 gene,
• Major histocompatibility complex,
• CD25 receptor,
• CD4

created over 15 years ago (2 March 2009)    last modified over 12 years ago (24 September 2012)   [ RDF ]   [ RelFinder ]